RESUMEN

The outcome of a 29-day residential addiction treatment programme for persons from Antigua and Barbuda with addiction to drugs or alcohol was assessed. All 100 patients entering the drug and alcohol treatment programme at Crossroads Centre Antigua between November 1998 and October 2002 were included. All patients were assessed with regards to drug or alcohol use or abstinence in November 2002 using telephone and mail follow-up as well as informal follow-up with families and other community contacts. Crossroads Centre Antigua is a 35 bed, 29-day residential treatment centre for drug and alcohol addiction serving patients from developed countries (85%) and from the Caribbean region (15%). Patients records were also reviewed to obtain age, gender, ethnicity, drug of choice, years of problematic use, completion of the 29 day programme, family member participation at Crossroads Centre Antigua (a four-day programme) and acceptance of halfway house placement. Of the 100 Antiguan patients admitted, 46 (46%) were abstinent (non-relapsers) at average 20.7+/-14.7 months after treatment. Abstinence did not have to be continuous. Forty-nine were known to be using drug or alcohol (49%) and five (5%) were lost to follow-up and considered to be using drugs (relapsers). Age (37.5 vs 41.1 years), gender (28% vs 22% female), ethnicity (87% vs 87% Afro-Caribbean), years of harmful use (12.7 vs 12.5 years) did not differ significantly between relapsers and non-relapsers. Crack cocaine use (67% vs 65%) and alcohol use (26% vs 31%) as primary addiction did not differ significantly between relapsers and non-relapsers. Relapsers were significantly less likely to complete the 29- day programme (81% vs 100%, p < 0.01), have family members participate at Crossroads (32% vs 54%, p < 0.05) or accept halfway house placement (4% vs 54%, p < 0.001). In conclusion, abstinence was achieved in 46% of those entering treatment, in 51% completing treatment, in 60% whose families participated and in 92% of those accepting halfway house placement.

Asunto(s)

RESUMEN

The outcome of a 29-day residential addiction treatment programme for persons from Antigua and Barbuda with addiction to drugs or alcohol was assessed. All 100 patients entering the drug and alcohol treatment programme at Crossroads Centre Antigua between November 1998 and October 2002 were included. All patients were assessed with regards to drug or alcohol use or abstinence in November 2002 using telephone and mail follow-up as well as informal follow-up with families and other community contacts. Crossroads Centre Antigua is a 35 bed, 29-day residential treatment centre for drug and alcohol addiction serving patients from developed countries (85%) and from the Caribbean region (15%). Patients records were also reviewed to obtain age, gender, ethnicity, drug of choice, years of problematic use, completion of the 29 day programme, family member participation at Crossroads Centre Antigua (a four-day programme) and acceptance of halfway house placement. Of the 100 Antiguan patients admitted, 46 (46%) were abstinent (non-relapsers) at average 20.7+/-14.7 months after treatment. Abstinence did not have to be continuous. Forty-nine were known to be using drug or alcohol (49%) and five (5%) were lost to follow-up and considered to be using drugs (relapsers). Age (37.5 vs 41.1 years), gender (28% vs 22% female), ethnicity (87% vs 87% Afro-Caribbean), years of harmful use (12.7 vs 12.5 years) did not differ significantly between relapsers and non-relapsers. Crack cocaine use (67% vs 65%) and alcohol use (26% vs 31%) as primary addiction did not differ significantly between relapsers and non-relapsers. Relapsers were significantly less likely to complete the 29- day programme (81% vs 100%, p < 0.01), have family members participate at Crossroads (32% vs 54%, p < 0.05) or accept halfway house placement (4% vs 54%, p < 0.001). In conclusion, abstinence was achieved in 46% of those entering treatment, in 51% completing treatment, in 60% whose families participated and in 92% of those accepting halfway house placement

Se evaluó el resultado de un programa de 29 días de tratamiento residencial de la adicción para personas de Antigua y Barbuda adictas a drogas o alcohol. Fueron incluidos todos los pacientes de un total de 100 que entraron a formar parte del programa de tratamiento contra las drogas y el alcohol en el Crossroads Centre Antigua entre noviembre de 1998 y octubre de 2002. Todos los pacientes fueron evaluados en relación con el uso o la abstinencia de drogas o alcohol en noviembre 2002, mediante un seguimiento por vía telefónica o correo, así como a través de un seguimiento informal con familiares u otros contactos en la comunidad. El Crossroads Centre Antigua es un centro de 35 camas para el tratamiento residencial por 29 días de la adicción a las drogas o el alcohol. El centro presta servicios a pacientes de los países desarrollados (85%) y de la región del Caribe (15%). También se revisaron los récords médicos de los pacientes para obtener datos sobre edad, sexo, etnicidad, droga de elección, años de uso problemático, cumplimiento del programa de 29 días, participación de miembros de la familia en el Crossroads Centre Antigua (un programa de cuatro días) y aceptación de su inclusión en una "casa de medio camino." De los 100 pacientes antigüenses admitidos, 46 (46%) eran abstinentes (no recayentes) en un momento determinado, ubicado como promedio 20.7 ± 14.7 meses después del tratamiento. La abstinencia no tenía que ser continua. Se sabía que 49 (49%) estaban usando drogas o alcohol, y cinco (5%) fueron dados por perdidos del seguimiento y de regreso al uso de las drogas (recayentes). La edad (37.5 vs 41.1 años), sexo (28% varones vs 22% hembra), etnicidad (87% vs 87% Afrocaribeños), y los años de consumo perjudicial (12.7 vs 12.5 años) no presentaron diferencias significativas entre los recayentes y los no recayentes. El uso de la cocaína-crack (67% vs 65%) y el uso del alcohol (26% vs.31%) como adicción primaria, no mostró diferencias significativas entre los recayentes y los no recayentes. Los recayentes mostraron una probabilidad significativamente menor en cuanto a completar el programa de 29 días (81% vs 100%, p < 0.01), hacer que miembros de su familia participaran en Crossroads (32% vs 54%, p < 0.05) o aceptar su inclusión en la casa de medio camino (4% vs 54%, p < 0.001). En conclusión, se logró abstinencia en el 46% de los que adoptaron el tratamiento, el 51% de los que completaron el tratamiento, el 60% de aquellos cuyas familias participaron, y el 92% de quienes aceptaron ser ubicados en la casa de medio camino.

Asunto(s)

RESUMEN

The present study evaluated the ability of DHV-PGE2ME, a topically effective 16-vinyl prostaglandin E2 analogue, to improve the tolerance of skin flaps to a period of ischemia. DHV-PGE2ME and placebo were applied to bilateral island flaps on 70 anesthetized rats; then the vascular pedicle of each flap was clamped for 10 hours. Treated flaps evidenced significantly better reperfusion, as documented by quantification of fluorescein dye delivery at 90 minutes after clamp release, and they had significantly greater ultimate viability (p less than 0.05, by ANOVA). While less than 3 percent of untreated flaps survived, those treated with 1.75 and 17.5 microgram/cm2 of drug evidenced 76 and 86 percent survival, respectively. Treatment of a given flap did not affect its contralateral mate, since there was no evidence of a systemic effect. Especially since its effect can be limited to the site of application, DHV-PGE2ME should be valuable for the treatment of compromised perfusion in a variety of settings.

Asunto(s)

RESUMEN

The records of five neonates born to mothers treated with intravenously administered magnesium sulfate for tocolysis were retrospectively reviewed to assess the presence of radiographic, clinical, and biochemical abnormalities. Two infants had radiographic bony abnormalities; one had frank rachitic changes and dental enamel hypoplasia. One of these patients, as well as an additional infant, had transient hypocalcemia. We hypothesize that prolonged infusion of magnesium sulfate, especially when initiated during the second trimester, may lead to fetal parathyroid gland suppression with consequent abnormalities resembling rickets.

Asunto(s)

RESUMEN

This study evaluated oral ingestion as the route of fluorescein administration for fluorescence assessment of skin perfusion. In 10 anesthetized rats, dorsal pedicle flaps were raised to produce graded perfusion; then fluorescein (7.5 mg/kg) was administered via an oropharyngeal tube. Quantification of skin fluorescence, performed with the fiberoptic fluorometer 45 minutes after dye ingestion, delineated a significant difference between the perfusion of flap regions that remained viable and those that subsequently became dystrophic (p less than 0.05). The precision was equivalent to that previously reported after intravenous dye. In addition, the gradual delivery of dye after oral administration permitted monitoring of slope of uptake and time to peak. Each of these pharmacokinetic parameters delineated a significant difference between viable and nonviable sections. As measures of relative change in fluorescence, they are independent of skin color and thickness. This feature suggests that the oral route actually may improve the accuracy and reliability of the fluorescein test.

Asunto(s)